An international team of scientists has successfully tested an innovative in vivo CAR-T therapy, JY231, capable of treating severe autoimmune diseases with a single intravenous infusion. Published in the New England Journal of Medicine, the experimental treatment uses a harmless genetically modified viral vector to deliver genetic instructions directly into a patient’s T-lymphocytes, reprogramming them to target and destroy defective B-cells that produce autoantibodies. In a clinical trial involving 16 patients with treatment-resistant conditions such as multiple sclerosis, myasthenia gravis, and myopathy, the therapy demonstrated over 99% accuracy. Within two months, patients’ bone marrow began producing healthy immune cells, and after six months of observation, participants exhibited significant clinical improvements, including the elimination of chronic fatigue and the partial restoration of cognitive and muscular functions. Researchers are now preparing for large-scale randomized trials to definitively confirm the method’s long-term safety and efficacy.
Among 16 patients with refractory neurologic autoimmune disorders, lentiviral CD19 CAR T-cell therapy was associated with manageable side effects, complete B-cell depletion, and preliminary clinical improvement across disease groups.